Torsemide

Selected standard tablets treat edema associated with heart failure, renal disease or hepatic disease and treat hypertension, alone or with other antihypertensives. Soaanz is indicated in adults for edema associated with heart failure or renal disease; its label does not include hepatic edema or hypertension. Standard labeling states that no controlled trial establishes torsemide-specific cardiovascular risk reduction. Do not claim Soaanz prevents hypokalemia/excessive urination or is superior to other loop diuretics.

This profile covers oral products, not a presumed current IV formulation, compounded liquid or veterinary torsemide. Current FDA records list selected standard 5/10/20/100 mg products as Prescription. Soaanz has 40 mg Prescription while 20/60 mg are Discontinued. Status is not local availability; product changes require the prescriber/pharmacist to verify formulation and dose.

Take once daily; titration is clinician supervised and follows response and laboratory/volume status. The label describes food as not changing overall standard-tablet bioavailability or diuretic activity.

Manufacturer-linked approved PI starts at 20 mg once daily for adult cardiac/renal edema and approximately doubles if response is inadequate; >200 mg is not adequately studied. FDA currently lists 20 and 60 mg Soaanz as Discontinued and 40 mg as Prescription. The available status does not authorize starting every patient at 40 mg or independently splitting an unscored tablet. Have the prescriber/pharmacist establish a verified product/dose plan; standard generic tablets should not be assumed to reproduce Soaanz’s exposure characteristics.

Use the actual prescribed product. Follow weight/edema/BP response and watch for overdiuresis; do not double missed doses or self-adjust a chronic regimen. Standard tablets and Soaanz have different food/peak-exposure profiles; maintaining the clinician’s dosing routine is preferable to changing meals or product to force a stronger effect. Acute deterioration, inability to maintain intake or fainting needs clinical assessment.

Do not use with hypersensitivity to the product/torsemide, anuria or hepatic coma. Nonanuric chronic renal failure is an indication context, not the same as anuria. Suspected hepatic encephalopathy or profound volume depletion requires urgent reassessment rather than routine dose escalation.

Neither the selected standard-tablet label nor complete manufacturer-linked Soaanz PI carries a boxed warning. Both still require monitoring for excessive diuresis, renal dysfunction and electrolyte disturbances.

Excess urination is a reported standard-tablet effect; clinically important events include dehydration/hypotension, electrolyte abnormalities, worsening kidney function and hearing symptoms. Rare postmarketing reports include severe skin reactions, blood-count abnormalities, pancreatitis and urinary retention; frequency/causality cannot be reliably estimated. Overdose causes exaggerated fluid/electrolyte depletion and needs supportive replacement and assessment. Torsemide is not dialyzable.

Review co-treatments before changing dose or adding a drug.

Cirrhotic-edema standard-tablet regimens require an aldosterone antagonist or potassium-sparing diuretic, but all potassium supplements/partners still need lab-guided review. Do not infer that a potassium-sparing partner or Soaanz eliminates electrolyte risk.

Pediatric safety/effectiveness are not established. Labels discuss renal calcification/patent-ductus concerns observed with other loop-diuretic exposure in young infants; do not relabel those observations as proven torsemide-specific rates. Trials did not show specific age-related safety/efficacy differences, but older patients still need volume, renal and electrolyte assessment.

Nonanuric renal impairment may reduce delivery of drug to its tubular site and blunt response even when total plasma clearance changes little. Use indication-specific starting doses and clinical response, not an invented eGFR table. Anuria is contraindicated. High-dose torsemide did not establish improved steady-state fluid retention in studied dialysis patients; very high acute-renal-failure study doses were associated with seizures and are not routine dose recommendations.

Standard-label cirrhotic edema starts at 5–10 mg daily with an aldosterone antagonist or potassium-sparing agent; hospital initiation is preferred because rapid shifts can cause hepatic coma/encephalopathy. Consider holding/stopping for new/worsening encephalopathy. Soaanz has no hepatic-edema indication. Hepatic coma is contraindicated with both; PK observations do not override it.

Human pregnancy data are insufficient to quantify major-malformation/miscarriage risk; use only after individual assessment of indication and alternatives. There are no human milk/infant-effect data in these labels, and diuretics can suppress lactation. Do not infer established safety from animal studies or from routine adult use.

Torsemide inhibits the sodium-potassium-chloride carrier in the thick ascending loop of Henle, increasing sodium/chloride/water excretion. Standard tablets start diuresis within about an hour, peak in the first/second hour and act about 6–8 hours; Soaanz’s peak diuretic effect is described within the first four hours with similar stated duration. This does not establish absence of potassium loss or better clinical outcomes.

Torsemide is >99% protein bound, metabolized mainly via CYP2C9 and cleared by hepatic metabolism plus proximal tubular secretion; typical half-life is about 3.5 hours. Standard-tablet bioavailability is about 80%, with peak levels within one hour; food delays peak without changing overall exposure. Soaanz peaks around 2.5 hours; a high-fat meal substantially raises Cmax/AUC, though no clinically significant diuretic change was observed in that study. Those results do not justify unsupervised dose conversion.

Track weight/edema, BP including symptoms, volume status, urine response, kidney function, electrolytes and glucose periodically and according to dose/illness risk. Review gout and hearing symptoms when relevant. Recheck after dose/product changes or added NSAIDs, lithium, CYP2C9 modifiers or nephrotoxins. Cirrhotic patients need mental-status and fluid/electrolyte assessment. Routine torsemide concentration testing is not required by the labels.

Report marked thirst, weakness, cramps, dizziness, fainting, poor intake, vomiting/diarrhea, reduced urine or hearing symptoms. Label counseling advises stopping after syncope until the prescriber is consulted. Discuss NSAIDs before use and maintain the prescribed fluid/salt plan rather than assuming extra water is always appropriate in heart failure. Obtain clear instructions for missed doses and intercurrent illness; do not substitute tablets or escalate because swelling persists.

Selected Teva 20 mg standard tablet is white/off-white, round and scored, marked PA and 917; bottle of 100 NDC 50111-917-01. Current FDA ANDA076346 lists its20 mg product Prescription. This example is package identity, not evidence of local stock.

Selected standard tablets: 5,10,20 and100 mg. Soaanz’s manufacturer-linked PI lists 20,40 and 60 mg film-coated tablets, but current FDA status is 40 mg Prescription and 20/60 mg Discontinued. The current 40 mg label record describes an unscored round orange T40 tablet. Do not independently split or substitute based on the shared ingredient. No injectable availability is inferred here.

Standard tablets specify 20–25°C, dispensed in a tight light-resistant container with child-resistant closure as required. Soaanz specifies 20–25°C with excursions 15–30°C. Follow the actual package expiry and keep medicine away from children. Product identity and current strength availability need pharmacist verification before a formulation change.